Business
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- -- $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 -- NAARDEN, the Netherlands and MIAM
About this update from Newamsterdam Pharma Company N.v.
[{"type":"image","alt":"NewAmsterdam Pharma N.V.","displaySize":"","headline":null,"caption":"NewAmsterdam Pharma N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/7a9e14494624e24d3616c1924c4ac204"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RcYte0v4ksn9z_SQU3xbGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7a9e14494624e24d3616c1924c4ac204","width":300,"height":75}},"lazy":false},{"type":"text","content":"-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 --","length":146,"tagName":"p"},{"type":"text","content":"-- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- ","length":119,"tagName":"p"},{"type":"text","content":"-- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metabolic syndrome expected by year-end 2026 -- ","length":126,"tagName":"p"},{"type":"text","content":"-- $728.9 million in cash, cash equivalents and marketable securities at December 31, 2025 --","length":93,"tagName":"p"},{"type":"text","content":"NAARDEN, the Netherlands and MIAMI, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced financial results for the full year ended December 31, 2025 and provided a corporate update.","length":543,"tagName":"p"},{"type":"text","content":"“2025 marked a year of meaningful clinical and regulatory progress for NewAmsterdam, as we advanced our mission to bring a potentially transformative therapy with obicetrapib to cardiometabolic disease patients who continue to struggle to reach their LDL-C goals,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. “Marketing Authorization Applications for obicetrapib and the fixed dose combination were accepted for review by the European Medicines Agency (“EMA”), Switzerland, and United Kingdom regula...